BCG诱导后维持治疗:BCG与吉西他滨/多西他赛疗效比较
该回顾性研究比较了初治非肌层浸润性膀胱癌(NMIBC)患者在接受BCG诱导后,分别使用BCG维持或吉西他滨/多西他赛(Gem/Doce)维持的肿瘤学结局与安全性。结果显示两组3年无复发生存率、高级别无复发生存率、无进展生存率和无转移生存率均无显著差异,但Gem/Doce维持组不良事件更少,耐受性更好。
要点
- BCG诱导后Gem/Doce维持与BCG维持的3年肿瘤学结局相当
- Gem/Doce维持组不良事件发生率显著低于BCG维持组(6.7% vs 28%)
- Gem/Doce可作为BCG不耐受或短缺时的替代维持方案
核心结论
- BCG诱导后序贯Gem/Doce维持治疗可获得与BCG维持相当的肿瘤学结局,且耐受性更优,可作为BCG不耐受或短缺时的替代选择。
研究设计与样本
- 回顾性研究,纳入2016-2026年初治NMIBC接受BCG诱导后行BCG维持(n=98)或Gem/Doce维持(n=30)的患者,共128例。
主要发现
- BCG组中位随访75.0个月(IQR 66.7-86.5),Gem/Doce组22.5个月(IQR 14.8-42.9),P<0.001。
- 3年无复发生存率BCG组80.0% vs Gem/Doce组83.8%,P=0.8。
- 3年高级别无复发生存率83.4% vs 92.2%,P=0.7;3年无进展生存率90.0% vs 96.6%,P=0.4;3年无转移生存率96.8% vs 100.0%,P=0.3。
- 多变量Cox回归显示Gem/Doce vs BCG维持与疾病复发无关(HR 1.04;95%CI 0.39-2.83;P>0.9)。
- Gem/Doce维持组不良事件报告率6.7% vs BCG组28%,P=0.02,维持期无严重事件。
临床怎么用
- 对于BCG诱导后的NMIBC患者,若存在BCG不耐受或供应短缺,可考虑采用Gem/Doce维持治疗。
局限性
- 回顾性设计,Gem/Doce队列样本量相对较小。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To compare the oncologic outcomes and safety profiles of Bacillus Calmette-Guérin (BCG) versus gemcitabine/docetaxel (Gem/Doce) maintenance following BCG induction in treatment-naïve non-muscle-invasive bladder cancer (NMIBC). METHODS: We identified patients with treatment-naive NMIBC who received induction BCG followed by maintenance BCG per the Southwest Oncology Group Cancer Research Network protocol or Gem/Doce monthly for 1 year (2016-2026). Oncological outcomes included recurrence-free survival (RFS), high-grade RFS, progression-free survival, and metastasis-free survival. Adverse events were systematically assessed to evaluate treatment tolerability. RESULTS: Overall, 128 patients received BCG induction followed by either BCG maintenance (n = 98; 76.6%) or Gem/Doce maintenance (n = 30; 23.4%). After a median follow-up of 75.0 months (interquartile range [IQR] 66.7-86.5) in the BCG group and 22.5 months (IQR 14.8-42.9) in the Gem/Doce group (P < 0.001), 3-year RFS (80.0% vs. 83.8%; P = 0.8), 3-year high-grade RFS (83.4% vs. 92.2%; P = 0.7), 3-year progression-free survival (90.0% vs. 96.6%; P = 0.4), and 3-year metastasis-free survival (96.8% vs. 100.0%; P = 0.3) were comparable between the BCG and Gem/Doce maintenance groups, respectively. Multivariable Cox regression analysis confirmed that Gem/Doce versus BCG maintenance was not associated with disease recurrence (hazard ratio 1.04; 95% confidence interval 0.39-2.83; P > 0.9). Overall, Gem/Doce maintenance was better tolerated, with fewer patients reporting adverse events (6.7% vs. 28%, P = 0.02) and no severe events observed during the maintenance phase. Limitations of the study include its retrospective design and the relatively small sample size of the Gem/Doce cohort. CONCLUSION: Sequential Gem/Doce maintenance following BCG induction achieved oncologic outcomes comparable to those with BCG maintenance, with improved tolerability, highlighting its feasibility as an alternative in cases of BCG intolerance or shortage.
引用
- Gabriel PE, Zhu A, Karim CG, et al. Outcomes of maintenance BCG versus gemcitabine/docetaxel following BCG induction in NMIBC. BJU Int. 2026. PMID: 42400296. doi:10.1111/bju.70375
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。